These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16633364)

  • 21. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
    Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
    Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis.
    Artero A; Tarín JJ; Cano A
    Semin Thromb Hemost; 2012 Nov; 38(8):797-807. PubMed ID: 23111860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-steroidal anti-estrogens in the treatment of breast cancer.
    Barker S
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1085-91. PubMed ID: 17209526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of the new selective estrogen receptor modulators.
    Palacios S
    Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer.
    Jia N; Wang J; Li Q; Tao X; Chang K; Hua K; Yu Y; Wong KK; Feng W
    Oncotarget; 2016 Dec; 7(51):84785-84797. PubMed ID: 27764784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signaling by estrogens.
    Cheskis BJ; Greger JG; Nagpal S; Freedman LP
    J Cell Physiol; 2007 Dec; 213(3):610-7. PubMed ID: 17886255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [SERMs: mechanisms of action and therapeutic indications].
    Malville E
    Ann Endocrinol (Paris); 2003 Dec; 64(6):481-2. PubMed ID: 15080159
    [No Abstract]   [Full Text] [Related]  

  • 29. ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
    Zeng K; Wu Y; Wang C; Wang S; Sun H; Zou R; Sun G; Song H; Liu W; Sun N; Wei S; Liu W; Su Y; Zhou T; Zhang Y; Zhao Y
    Cancer Sci; 2020 Jun; 111(6):2062-2077. PubMed ID: 32279431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.
    Kastrati I; Edirisinghe PD; Hemachandra LP; Chandrasena ER; Choi J; Wang YT; Bolton JL; Thatcher GR
    PLoS One; 2011; 6(11):e27876. PubMed ID: 22140478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective oestrogen receptor modulators--current and future brain and behaviour applications.
    Halbreich U; Kahn LS
    Expert Opin Pharmacother; 2000 Dec; 1(7):1385-98. PubMed ID: 11249472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometrial cancer--surprising reports.
    Speroff L
    Maturitas; 2005 Aug; 51(4):329-33. PubMed ID: 16039404
    [No Abstract]   [Full Text] [Related]  

  • 34. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties.
    Singh MN; Stringfellow HF; Paraskevaidis E; Martin-Hirsch PL; Martin FL
    Cancer Treat Rev; 2007 Apr; 33(2):91-100. PubMed ID: 17178195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
    Bläuer M; Heinonen PK; Rovio P; Ylikomi T
    Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
    Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
    Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N'-nitro-N-nitrosoguanidine.
    Takahashi M; Shimomoto T; Miyajima K; Yoshida M; Katashima S; Uematsu F; Maekawa A; Nakae D
    Cancer Lett; 2004 Jul; 211(1):1-9. PubMed ID: 15194211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
    Boruban MC; Altundag K; Kilic GS; Blankstein J
    Eur J Cancer Prev; 2008 Apr; 17(2):133-8. PubMed ID: 18287870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
    Bose SK; Gibson W; Giri S; Nath N; Donald CD
    Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.